8-K: Cyclo Therapeutics Secures $2 Million in Convertible Note Financing from Rafael Holdings

Cyclo Therapeutics has entered into a $2 million convertible note agreement with Rafael Holdings to bolster working capital and general corporate operations.

Summary

• Cyclo Therapeutics has secured a $2 million convertible promissory note from Rafael Holdings, a major shareholder.
• The note carries a 5% annual interest rate and matures on November 11, 2024.
• The principal amount can be prepaid by Cyclo Therapeutics at any time.
• Rafael Holdings has the option to convert the note into common stock under certain conditions.
• Conversion is automatic upon a qualified financing event, which is defined as a capital raise of at least $8 million.
• Conversion is also possible at Rafael's option if a sale transaction occurs before the note is repaid.
• The conversion price is the lesser of $0.95 or 80% of the price paid in a qualified financing or implied value in a sale transaction.
• The funds will be used for working capital and general corporate purposes.

Sentiment

Score: 7

Explanation: The document indicates a positive development for the company by securing funding, but also introduces potential risks associated with debt and dilution. The sentiment is moderately positive.

Positives

• The $2 million in funding provides Cyclo Therapeutics with additional working capital.
• The ability to prepay the note offers flexibility to the company.
• The conversion feature could be beneficial for both the company and Rafael Holdings if the company performs well.
• The interest rate of 5% is relatively low.

Negatives

• The note increases the company's debt obligations.
• The conversion of the note could dilute existing shareholders.
• Failure to repay the note could trigger an event of default and increase the interest rate to 12%.

Risks

• The company's ability to repay the note depends on its financial performance.
• The conversion of the note could dilute existing shareholders if the company's stock price does not increase.
• An event of default could lead to acceleration of the debt and potentially further financial difficulties.
• The company is reliant on a single investor for this funding.

Future Outlook

The company intends to use the proceeds of the note for working capital and general corporate purposes, and the note may convert to equity under certain conditions.

Management Comments

• The company intends to use the proceeds of the Note for working capital and general corporate purposes.

Industry Context

This type of financing is common for companies seeking to raise capital, particularly in the biotech sector, where cash flow can be unpredictable. The involvement of a major shareholder like Rafael Holdings indicates a strong level of confidence in the company's future.

Comparison to Industry Standards

• Convertible notes are a common financing tool for small to mid-cap biotech companies, often used as a bridge to larger equity raises.
• The 5% interest rate is relatively standard for this type of financing, although it can vary based on the company's risk profile and market conditions.
• The conversion terms, including the discount to the qualified financing price, are also typical in these types of agreements.
• Comparable companies in the biotech space often use similar financing structures to fund research and development and operations.

Related Party Transactions

• The convertible note agreement is a related party transaction as Rafael Holdings is a significant shareholder of Cyclo Therapeutics.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• The funding provides the company with resources to continue operations, which is positive for employees.
• The funding may enable the company to continue its research and development efforts, which could benefit customers in the long term.
• The company's ability to repay the note will impact its creditors.

Next Steps

• The company will use the funds for working capital and general corporate purposes.
• The company may seek a qualified financing event to trigger the automatic conversion of the note.
• Rafael Holdings may elect to convert the note into common stock at their discretion.

Key Dates

Keywords

convertible note, financing, Rafael Holdings, working capital, common stock, debt, conversion, qualified financing, sale transaction